Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 5, Issue 2, 2009, Pages 178-183

  Cesur, Hacer ^a   Rubinstein, Israel ^b,c   Pai, Ashwini ^b   Önyüksel, Hayat ^a,b  

^a University of Illinois at Chicago   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

DSPE PEG2000 and EPC; Indisulam; PEGylated phospholipids; Sterically stabilized mixed micelles; Sterically stabilized simple micelles; Water insoluble anticancer drug

Indexed keywords

DSPE-PEG2000 AND EPC; INDISULAM; PEGYLATED PHOSPHOLIPIDS; STERICALLY STABILIZED MIXED MICELLES; STERICALLY STABILIZED SIMPLE MICELLES;

CELL CULTURE; CHROMATOGRAPHIC ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PRESSURE LIQUID CHROMATOGRAPHY; LIGHT SCATTERING; MEDICAL NANOTECHNOLOGY; PHOSPHOLIPIDS; POLYETHYLENE GLYCOLS;

MICELLES;

1,2 DISTEAROYLGLYCERO 3 PHOSPHOETHANOLAMINE N METHOXYPOLY(ETHYLENE GLYCOL 2000); INDISULAM; MACROGOL 2000; NANOPARTICLE; PHOSPHATIDYLCHOLINE; PHOSPHOETHANOLAMINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN MCF 7; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG FORMULATION; DRUG STABILITY; FREEZE DRYING; HUMAN; HUMAN CELL; MICELLE; NANOENCAPSULATION; NANOMICELLE; NEOPLASM; PARTICLE SIZE; PRECIPITATION; SOLUBILIZATION; STEREOSPECIFICITY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; MICELLES; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; PARTICLE SIZE; PHOSPHOLIPIDS; SOLUBILITY; SULFONAMIDES;

EID: 67349127496     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2008.09.001     Document Type: Article

References (27)

1. Ashok B., Arleth L., Hjelm R.P., Rubinstein I., and Önyüksel H. In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporation. J Pharm Sci 93 (2004) 2476-2487
2. Krishnadas A., Rubinstein I., and Önyüksel H. Sterically stabilized phospholipid mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs. Pharm Res 20 (2003) 297-302
3. Önyüksel H., Ikezaki H., Patel M., Gao X.P., and Rubinstein I. A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo. Pharm Res 16 (1999) 155-160
4. Koo O.M., Rubinstein I., and Önyüksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine 1 (2005) 193-212
5. Lukyanov A.N., and Torchilin V.P. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev 56 (2004) 1273-1289
6. Lukyanov A.N., Gao Z., Mazzola L., and Torchilin V.P. Polyethylene glycol-diacyllipid micelles demonstrate increased accumulation in subcutaneous tumors in mice. Pharm Res 19 (2002) 1424-1429
7. Koo O.M., Rubinstein I., and Önyüksel H. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine. Nanomedicine 1 (2005) 77-84
8. Hammad M.A., and Muller B.W. Solubility and stability of lorazepam in bile salt/soya phosphatidylcholine-mixed micelles. Drug Dev Ind Pharm 25 (1999) 409-417
9. Gabizon A., Shmeeda H., Horowitz A.T., and Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev 56 (2004) 1177-1192
10. Owa T., Yoshino H., Okauchi T., Yoshimatsu K., Ozawa Y., Sugi N.H., et al. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J Med Chem 42 (1999) 3789-3799
11. Yamada Y., Yamamoto N., Shimoyama T., Horiike A., Fujisaka Y., Takayama K., et al. Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days. Cancer Sci 96 (2005) 721-728
12. Ozawa Y., Sugi N.H., Nagasu T., Owa T., Watanabe T., Koyanagi N., et al. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur J Cancer 37 (2001) 2275-2282
13. Smyth J., Aamdal S., Awada A., Dittrich C., Caponigro F., Schoffski P., et al. Phase II study of E7070 in patients with metastatic melanoma. Ann Oncol 16 (2005) 158-161
14. Fukuoka K., Usuda J., Iwamoto Y., Fukumoto H., Nakamura T., Yoneda T., et al. Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Invest New Drugs 19 (2001) 219-227
15. Abbate F., Casini A., Owa T., Scozzafava A., and Supuran C.T. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett 14 (2004) 217-223
16. Tripathy D. Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials. Oncologist 12 (2007) 375
17. Dittrich C., Zandvliet A.S., Gneist M., Huitema A.D., King A.A., and Wanders J. A phase I and pharmacokinetic study of indisulam in combination with carboplatin. Br J Cancer 96 (2007) 559-566
18. Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., et al. Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays. Mol Cancer Ther 4 (2005) 399-412
19. Raymond E., ten Bokkel Huinink W.W., Taieb J., Beijnen J., Faivre S., Wanders J., et al. Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer. J Clin Oncol 20 (2002) 3508
20. Yokoi A., Kuromitsu J., Kawai T., Nagasu T., Sugi N.H., Yoshimatsu K., et al. Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis. Mol Cancer Ther 1 (2002) 275-286
21. Punt C., Fumoleau P., van de Walle B., Faber M., Ravic M., and Campone M. Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-Early Clinical Studies Group (ECSG). Ann Oncol 12 (2001) 1289-1293
22. Zandvliet A.S., Copalu W., Schellens J.H., Beijnen J.H., and Huitema A.D. Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes. Drug Metab Dispos 34 (2006) 1041-1046
23. Papazisis K.T., Geromichalos G.D., Dimitriadis K.A., and Kortsaris A.H. Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods 208 (1997) 151-158
24. Vichai V., and Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1 (2006) 1112-1116
25. Lim S.B., Rubinstein I., and Önyüksel H. Freeze drying of peptide drugs self-associated with long-circulating, biocompatible and biodegradable sterically stabilized phospholipid nanomiclles. Int J Pharm 356 (2008) 345-350
26. Zhang J.X., Hansen C.B., Allen T.M., Boey A., and Boch R. Lipid-derivatized poly (ethylene glycol) micellar formulations of benzoporphyrin derivatives. J Control Release 86 (2003) 323-338
27. Hauss J.D. Oral lipid-based formulations: enhancing the bioavailability of poorly water-soluble drugs (drugs and the pharmaceutical sciences) 170 (2007), Informa Healthcare, New York 158-168